← Look up another trial

A Study of CJC-1134-PC Injection in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues

NCT07057271 on ClinicalTrials.gov Phase 3 Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd. (industry) Started 2021-05-27 Completed
Riskier than 14% of active trials
this trial: 9% 0% 36%

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (1,463 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

How it ended

Completed on 2023-02-21, after 2021-05-27 start.

The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.

Termination over time, as the model saw it at the start

0% 25% 50% 75% 100% 0123456 yr completed 88% terminated 11%

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-02-21. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

What moved the score

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

The trial

Design

Phase
3 (typical: 2)
Number of arms
2
Allocation
randomized
Design
parallel
Primary purpose
treatment
Blinding
quadruple (typical: none)
Has a data monitoring committee
No (typical: 56% yes)
Responsible party
sponsor
Collaborators
0
Keywords listed
0 (typical: 1)

Who can join

Minimum age
18
Maximum age
70 (typical: 71)
Sex
all
Accepts healthy volunteers
No (typical: 9% yes)

Sponsor's track record

Sponsor type
industry (typical: academic or other)
Sponsor's past trials
0 (typical: 32)
Sponsor's past termination rate
no earlier finished trials (typical: 9.9%)
Trials the sponsor started in the prior 2 years
1 (typical: 19)

Drug's FDA history

Drugs with FDA adverse-event history
0 (typical: 1)
Drug has FAERS history
No (typical: 64% yes)
Drug's FAERS reports before start
0 (typical: 2148)
Drug's FAERS reports in the prior 12 months
0 (typical: 412.5)
Drug's FAERS reports marked serious
no FAERS history (typical: 85.6%)
Drug's FAERS reports with a death
no FAERS history (typical: 15.9%)

Disease area and drugs

Disease areas
none of the 14 tracked areas
Drugs matched to FDA substances
none matched

Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.

Similar finished trials

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.